Support teaching, research, and patient care.
Dr. Christiane Haeffele earned her medical degree from the Duke University School of Medicine in Durham, North Carolina. She completed a combined medicine and pediatric residency at Harvard University in Boston, Massachusetts at the Brigham and Women's Hospital and Boston Children's Hospital. She also completed the Doris and Howard Hiatt Residency in Global Health Equity and Internal Medicine program, working on oncology infrastructure in Rwanda in partnership with the Rwandan Ministry of Health and Partners in Health. She completed her fellowship in adult cardiology and sub-specialized training in adult congenital heart disease and echocardiography at Stanford Hospital. She served one year as a chief fellow for the general cardiology fellowship at Stanford. Dr. Haeffele is the Director of the Structural ECHO program at Stanford Hospital. She is the Program Director for the Advanced ECHO Imaging fellowship. Dr. Haeffele is also appointed Clinical Assistant Professor of Medicine and Pediatrics at Stanford University School of Medicine. Dr. Haeffele is a board certified cardiology physician. Her research interests include management of adults with congenital heart disease, echocardiography, structural heart disease and catheter based interventions, and the complexities of heart transplant in the adult with congenital heart disease.
Adult Congenital Heart Disease
Percutaneous or Surgical Mitral Valve Repair
This is a prospective, multicenter, open-label, randomized trial comparing mitral valve (MV)
transcatheter edge-to-edge repair (TEER) to surgical repair (1:1 ratio) in patients with
primary, degenerative mitral regurgitation (MR). The trial will be conducted in the U.S.,
Canada, Germany and the United Kingdom, and is designed as a strategy trial. Thus, all
devices legally marketed for TEER of primary degenerative MR in a particular country are
eligible to be used in this trial.
View full details
ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve
The objective of this study is to establish the safety and effectiveness of the Edwards
SAPIEN X4 Transcatheter Heart Valve (THV) in subjects with symptomatic, severe, calcific
aortic stenosis (AS).
Reducing Lung CongestIon Symptoms in Advanced Heart Failure
The objective of the RELIEVE-HF study is to provide reasonable assurance of safety and
effectiveness of the V-Wave Interatrial Shunt System by improving meaningful clinical
outcomes in patients with New York Heart Association (NYHA) functional Class II, Class III,
or ambulatory Class IV heart failure (HF), irrespective of left ventricular ejection
fraction, who at baseline are treated with guideline-directed drug and device therapies.
PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR
This study objective is to establish the safety and effectiveness of the Edwards SAPIEN 3 /
SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve systems in subjects with
moderate, calcific aortic stenosis.
Beating Heart Mitral Valve Repair With the HARPOON™ System
The objective of the study is to evaluate the safety and effectiveness of the HARPOON™ System
in the treatment of patients with severe degenerative mitral regurgitation (DMR).
CE Mark Study for the Harpoon Medical Device
The purpose of this study is to evaluate the safety and performance of the Harpoon Medical
device. It is anticipated, that the Harpoon Medical device will provide advantages over
current surgical interventions including: 1) a small minimally invasive incision, 2) no
sternotomy, 3) no cardiopulmonary bypass, 4) no aortic manipulation, 5) a direct path to the
valve plane, 6) performed on a beating heart, 7) real-time TOE-guided chordal length
adjustment and 8) less complicated procedure that is teachable and adoptable.
Stanford is currently not accepting patients for this trial.
For more information, please contact SPECTRUM, .
TRISCEND II Pivotal Trial
Pivotal trial to evaluate the safety and effectiveness of the Edwards EVOQUE tricuspid valve
MitraClip REPAIR MR Study
The objective of this randomized controlled trial (RCT) is to compare the clinical outcome of
MitraClip™ device versus surgical repair in patients with severe primary MR who are at
moderate surgical risk and whose mitral valve has been determined to be suitable for
correction by MV repair surgery by the cardiac surgeon on the local site heart team.
Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation
Prospective, controlled, multicenter clinical investigation with four trial cohorts:
Randomized, Non-repairable, Severe Mitral Annular Calcification (MAC) and Severe Mitral
Annular Calcification Continued Access Protocol (MAC CAP). Subjects in the Randomized cohort
will be randomized in a 1:1 ratio to the trial device or to the MitraClip system. Subjects in
the Non-repairable, Severe MAC, and Severe MAC CAP cohorts will receive the trial device.
The objective of the Clinical Trial to Evaluate the Safety and Effectiveness of Using the
Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral
Regurgitation (SUMMIT) is to evaluate the safety and effectiveness of the Tendyne
Transcatheter Mitral Valve System for the treatment of patients with symptomatic,
moderate-to-severe or severe mitral regurgitation or for patients with symptomatic mitral
valve disease due to severe mitral annular calcification.
This randomized controlled trial will provide the opportunity to evaluate the safety and
clinical benefits of the Tendyne Transcatheter Mitral Valve System compared to the MitraClip
System in patients with symptomatic, moderate-to-severe or severe mitral regurgitation,
within approved MitraClip indications. In addition, the safety and effectiveness of the
Tendyne Transcatheter Mitral Valve System will be evaluated in patients with severe mitral
annular calcification who are at prohibitive risk for mitral valve surgery. Patients who are
not suitable for mitral valve surgery for reasons other than severe mitral annular
calcification and are also not suitable for transcatheter repair with MitraClip, will be
enrolled in the Non-repairable cohort.
Subjects will be seen at screening, pre- and post-procedure, discharge, 30 days, 3 months, 6
months, and annually through 5 years.
Edwards CLASP TR EFS
Early feasibility study to assess the safety and performance of the Edwards PASCAL
Transcatheter Valve Repair System in tricuspid regurgitation
ACURATE IDE: Safety and Effectiveness Study of ACURATE Valve for Transcatheter Aortic Valve Replacement
To evaluate safety and effectiveness of the ACURATE Transfemoral Aortic Valve System for
transcatheter aortic valve replacement (TAVR) in subjects with severe native aortic stenosis
who are indicated for TAVR.
Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial
To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Valve Repair
System in patients with degenerative mitral regurgitation (DMR) who have been determined to
be at prohibitive risk for mitral valve surgery by the Heart Team, and in patients with
functional mitral regurgitation (FMR) on guideline directed medical therapy (GDMT)
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
Multi-center, global, prospective, non-randomized, interventional, pre-market trial. All
subjects enrolled with receive the study device.
2019-06 TRISCEND Study
Prospective, multi-center study to assess safety and performance of the Edwards EVOQUE
Tricuspid Valve Replacement System